All In Biotech

NDA 018959 · Hospira

Zinc Chloride In Plastic Container

Zinc Chloride · Injection

Priority review

Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1986

Jun 26, 1986

Approved uses

1

Original approval plus efficacy supplements

Registered trials

22

8 Phase 3, 0 recruiting

FAERS reports

25,335

14,263 serious, 1,542 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 13, 2026.

INDICATIONS AND USAGE Zinc 1 mg/mL (Zinc Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 26, 1986 Original approval · Type 5 - New Formulation or New Manufacturer · priority review
1 products under this application
  • ZINC CHLORIDE IN PLASTIC CONTAINER · ZINC CHLORIDE EQ 1MG ZINC/ML · INJECTABLE, INJECTION · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Zinc Chloride" as an intervention, any sponsor and status, largest first.

All 22 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue2,685
  • pain2,007
  • nausea1,991
  • diarrhoea1,922
  • headache1,903
  • off label use1,871
  • drug ineffective1,640
  • dyspnoea1,509
  • dizziness1,370
  • arthralgia1,363
  • fall1,278
  • asthenia1,265

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200486
2005100
2006115
2007117
2008144
2009199
2010282
2011284
2012188
2013443
2014591
2015937
20161,063
2017923
20181,056
20191,078
20201,835
20213,033
20223,318
20232,629
20242,494
20252,550
20261,870

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 37 on PubMed

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.